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Objective: Neurofilament light chains (NfL) are unique to neuronal cells, are shed to the cerebrospinal fluid (CSF),
and are detectable at low concentrations in peripheral blood. Various diseases causing neuronal damage have
resulted in elevated CSF concentrations. We explored the value of an ultrasensitive single-molecule array (Simoa)
serum NfL (sNfL) assay in multiple sclerosis (MS).
Methods: sNfL levels were measured in healthy controls (HC, n 5 254) and two independent MS cohorts: (1) cross-
sectional with paired serum and CSF samples (n 5 142), and (2) longitudinal with repeated serum sampling (n 5 246,
median follow-up 5 3.1 years, interquartile range [IQR] 5 2.0–4.0). We assessed their relation to concurrent clinical,
imaging, and treatment parameters and to future clinical outcomes.
Results: sNfL levels were higher in both MS cohorts than in HC (p < 0.001). We found a strong association between
CSF NfL and sNfL (b 5 0.589, p < 0.001). Patients with either brain or spinal (43.4pg/ml, IQR 5 25.2–65.3) or both
brain and spinal gadolinium-enhancing lesions (62.5pg/ml, IQR 5 42.7–71.4) had higher sNfL than those without
(29.6pg/ml, IQR 5 20.9–41.8; b 5 1.461, p 5 0.005 and b 5 1.902, p 5 0.002, respectively). sNfL was independently
associated with Expanded Disability Status Scale (EDSS) assessments (b 5 1.105, p < 0.001) and presence of relapses
(b 5 1.430, p < 0.001). sNfL levels were lower under disease-modifying treatment (b 5 0.818, p 5 0.003). Patients
with sNfL levels above the 80th, 90th, 95th, 97.5th, and 99th HC-based percentiles had higher risk of relapses
(97.5th percentile: incidence rate ratio 5 1.94, 95% confidence interval [CI] 5 1.21–3.10, p 5 0.006) and EDSS wors-
ening (97.5th percentile: OR 5 2.41, 95% CI 5 1.07–5.42, p 5 0.034).
Interpretation: These results support the value of sNfL as a sensitive and clinically meaningful blood biomarker to
monitor tissue damage and the effects of therapies in MS.
ANN NEUROL 2017;81:857–870
The clinical course of multiple sclerosis (MS) is highlyvariable, ranging from rapidly reversible episodes of
impairment to severe disability within months after disease
onset. Focal inflammation, chronic diffuse neuronal dam-
age, and failure of repair or compensation all contribute to
the development of permanent disability.1 Biomarkers
reflecting tissue damage and allowing the monitoring of sub-
clinical disease activity are highly desirable for assessment of
therapeutic response and prediction of disability in both
clinical studies and management of individual patients.2
Together with the medium and heavy subunits,
neurofilament light chain (NfL) represents one of the
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scaffolding proteins of the neuronal cytoskeleton and is
released in the extracellular space following axonal dam-
age.3 NfL levels are increased in the cerebrospinal fluid
(CSF) of MS patients as well as in degenerative and trau-
matic neurological diseases (eg, dementia, amyotrophic
lateral sclerosis, and spinal cord injury).4–9 CSF NfL lev-
els are further increased during relapses and are positively
associated with magnetic resonance imaging (MRI) lesion
load and disability scores in MS.10–12 Noteworthy, CSF
NfL levels have also been shown to be a marker of treat-
ment response in this disease.13–17 However, lumbar
punctures are relatively invasive procedures, limiting the
value of CSF NfL in routine clinical settings.
A commercially available enzyme-linked immuno-
sorbent assay (ELISA; UmanDiagnostics, Umea˚, Sweden)
can be used to measure CSF NfL, but is not recom-
mended for blood measurements. Using an electrochemi-
luminescence (ECL)-based assay, we have found
increased serum NfL (sNfL) concentrations in clinically
isolated syndrome (CIS) and MS patients.11,12,18,19 How-
ever, these studies were limited by the still relatively low
sensitivity of the assay.20 A novel single-molecule array
(Simoa) assay has shown 126- and 25-fold higher sensi-
tivity than the ELISA and ECL assays, respectively.20,21
This high sensitivity allows a more accurate quantifica-
tion of the low sNfL concentrations expected in healthy
controls (HC) and can help to better differentiate abnor-
mal from normal values. Recent studies using this assay
have shown that sNfL levels are increased in patients suf-
fering from acute brain damage or chronic neurodegener-
ative disorders.22–24
This study had several aims: (1) to obtain a pilot
estimate of the distribution of sNfL concentrations in
HC and to investigate the potential influence of age and
gender; (2) to compare paired sNfL and CSF NfL levels
in MS patients; (3) to investigate the association between
sNfL and number of T2 and contrast-enhancing lesions
in brain and spinal cord; (4) to investigate the association
between sNfL and clinical features, including occurrence
of relapses, worsening of disability, and treatment status;
and (5) to test whether elevated sNfL levels can predict
later disease activity and disability worsening.
Subjects and Methods
Clinical Settings, Patient Selection, and Sample
Collection
LUGANO COHORT. A cross-sectional cohort (n 5 142) was
recruited between 2004 and 2015 at the Neurocenter of South-
ern Switzerland (Lugano, Switzerland), where paired serum and
CSF samples are prospectively collected and stored as part of
the diagnostic workup.25 Inclusion criteria were: (1) a diagnosis
of CIS, relapsing–remitting MS (RRMS), primary progressive
MS (PPMS), secondary progressive MS (SPMS), or radiologi-
cally isolated syndrome (RIS)26; (2) availability of serum and
preferably also paired CSF samples at time of diagnosis; (3)
availability of demographic and clinical data at time of diagno-
sis; and (4) availability of brain and preferably also spinal cord
magnetic resonance images acquired as part of the diagnostic
workup at time of diagnosis. All brain and spinal MRI included
in the analysis were performed with a standardized protocol
and using 1.5T and 3T scanners (Siemens Sonata and Siemens
Skyra, Erlangen, Germany).27
SWISS MULTIPLE SCLEROSIS COHORT STUDY COHORT. A
longitudinal cohort (n 5 246) was recruited between 2009 and
2016 at the Neurologic Clinic and Policlinic, University Hospi-
tal Basel (Switzerland), as part of the Swiss Multiple Sclerosis
Cohort Study (SMSC), a prospective observational study in
which demographic, neuroimaging, and clinical data as well as
serum samples are collected every 6 or 12 months. Standardized
clinical assessments with functional system score and Expanded
Disability Status Scale (EDSS) calculation are performed by cer-
tified raters (http://www.neurostatus.net/).28,29 All samples are
collected within 8 days from the clinical visit and stored at
2808C following standardized procedures.25 Criteria for inclu-
sion in this study were: (1) a diagnosis of CIS, RRMS, PPMS,
or SPMS; (2) at least 2 but preferably 3 available serum sam-
ples collected at baseline and at follow-up (FU) visits 1 and 2;
(3) start of disease-modifying treatment (DMT) or switch to a
different DMT shortly after baseline sample and before first FU
sample (this only for CIS and RRMS patients); and (4) avail-
ability of demographic and clinical data at time of sample col-
lection including information on relapses and disability scores
as measured by standardized assessment of the EDSS.
HC. Serum samples from 254 HC were collected between
2004 and 2007 in the Neurologic Clinic and Policlinic, Univer-
sity Hospital Basel, as part of the international cohort study
GeneMSA (Genetic MS Associations).30 A 1-year FU serum
sample was available for 87 HC. Inclusion criteria were age 5
18 to 70 years and no diagnosis of MS as well as no known
cases of MS in the family.
STANDARD PROTOCOL APPROVALS, REGISTRATIONS,
AND PATIENT CONSENT. The study received ethical
approval by independent ethics committees of the participating
centers; all patients provided written, informed consent. The
SMSC is registered with ClinicalTrials.gov (NCT02433028).
CSF and sNfL Measurements
We developed and validated a Simoa NfL assay using the cap-
ture monoclonal antibody (mAB) 47:3 and the biotinylated
detector mAB 2:1 from UmanDiagnostics,31 transferred onto
the Simoa platform. mAB 47:3 was buffer exchanged and
diluted to 0.3mg/ml. Paramagnetic beads (4 3 106; Quanterix
Corporation, Lexington, MA) were buffer exchanged and acti-
vated using 0.5mg/ml 1-ethyl-3-(3-dimethylaminopropyl) car-
bodiimide (Quanterix), followed by a 30-minute incubation at
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room temperature (RT; HulaMixer; Thermo Fisher Scientific,
Waltham, MA). During a 2-hour incubation at RT (Hula-
Mixer) the diluted capture mAB was conjugated with the
washed and activated beads. Subsequently, the beads were
washed and blocked. After 3 washes, the conjugated beads were
suspended and stored at 48C. Biotinylated mAB 2:1 was
obtained from UmanDiagnostics and stored at 48C pending
analysis.
The assay was run on a Simoa HD-1 instrument (Quan-
terix) using a 2-step Assay Neat 2.0 protocol; 100ll of calibra-
tor/sample (diluent: Tris-buffered saline [TBS], 0.1% Tween
20, 1% milk powder, 400lg/ml Heteroblock [Omega Biologi-
cals, Bozeman, MT]), 25ll conjugated beads (diluent: TBS,
0.1% Tween 20, 1% milk powder, 300lg/ml Heteroblock),
and 20ll of mAB 2:1 (0.1lg/ml; diluent: TBS, 0.1% Tween
20, 1% milk powder, 300lg/ml Heteroblock) were incubated
for 47 cadences (1 cadence 5 45 seconds). After washing,
100ll of streptavidin-conjugated b-galactosidase (150pM;
Quanterix) was added, followed by a 7-cadence incubation and
a wash. Prior to reading, 25ll Resorufin b-D-galactopyranoside
(Quanterix) was added. Calibrators (neat) and samples (serum:
1:4 dilution; CSF: 1:10 dilution) were measured in duplicates.
Bovine lyophilized NfL was obtained from UmanDiagnostics.
Calibrators ranged from 0 to 2,000pg/ml for serum and from 0
to 10,000pg/ml for CSF measurements. Batch prepared calibra-
tors were stored at 2808C.
Intra- and interassay variability of the assay was evaluated
with 3 native serum and 3 native CSF samples in 22 and 12
consecutive runs on independent days, respectively. For serum,
the mean coefficients of variation (CVs) of duplicate determina-
tions for concentration were 5.6% (13.3pg/ml, sample 1), 6.9%
(22.5pg/ml, sample 2), and 5.3% (236.5pg/ml, sample 3). In
CSF, the mean intra-assay CVs were 2.5% (572.6pg/ml, sample
1), 0.7% (1,601.8pg/ml, sample 2), and 3.8% (6,110.2pg/ml,
sample 3). Interassay CVs for serum were 11.3% (sample 1),
9.3% (sample 2), and 6.4% (sample 3). In CSF, interassay CVs
were 10.1% (sample 1), 6.2% (sample 2), and 15.5% (sample
3). We used the concentration of the lowest calibrator fulfilling
acceptance criteria (accuracy 5 80–120%, CV of duplicate
determination  20%) as an estimate of the analytical sensitiv-
ity.32 The analytical sensitivity was 0.32pg/ml. All samples pro-
duced signals above the analytical sensitivity of the assay. Few
samples with intra-assay CVs > 20% were repeat measured.
Recovery rates ([concentration of spiked sample 2 concentra-
tion of native sample]/spiked concentration 3 100) were tested
in 4 serum and 4 CSF samples from HC spiked with 5, 50,
and 200pg/ml and 500 and 2,000pg/ml of NfL, respectively.
The mean recovery after spiking was 107% for serum and
121% for CSF. Parallelism and linearity of the assay for serum
and CSF were confirmed by serial dilution experiments.32
Statistics
Categorical variables were described by counts and percentages,
continuous and ordinal variables by median and interquartile
ranges (IQRs). For all analyses, NfL levels were log-transformed
to meet the normal assumption. The distribution of sNfL in
HC and its association with age was modeled by means of
Generalized Additive Models for Location, Scale, and Shape
(GAMLSS) using a Box-Cox t distribution according to Rigby
and Stasinopoulos,33 and cubic splines and percentile curves
were obtained. To quantify the variability, bootstrapping was
applied by drawing 100 random samples from the HC. From
each sample, the percentile curves were estimated and the final
reference percentiles across different ages represent averages over
the 100 replicates together with the bootstrap confidence inter-
vals (CIs).
In the cross-sectional Lugano cohort, linear regression
models were used to investigate the associations with log sNfL.
Linear generalized estimating equation (GEE) models were sim-
ilarly used to investigate associations with log sNfL in the
SMSC cohort with repeated measurements. In all linear models
with log sNfL as the dependent variable, regression coefficients
(denoted with “b” throughout this work) were back-
transformed to the original scale and therefore reflect multipli-
cative effects (ie, an estimate of 1.05 means an increase of
approximately 5% in sNfL).
In GEE models, different correlation structures were
investigated and model selection was performed based on quasi-
likelihood under the independence model criterion (QIC).34
Based on expert input and signals observed in the graphical
analysis, several interaction terms were investigated, and the
final model was selected based on the QIC. To investigate the
course of sNfL after treatment initiation, a linear GEE was
used with time under treatment and baseline sNfL as additional
covariates in the multivariate model, thereby excluding treat-
ment status. This analysis was performed on all samples after
treatment start.
Patients’ sNfL levels were finally categorized based on the
percentiles derived from the HC samples. Clinically meaningful
events (relapses, annualized relapse rate [ARR], or EDSS wors-
ening, both before and after sample collection) were then tested
for association with sNfL levels above versus below various per-
centile cutoffs using GEE models. These analyses were per-
formed for the percentile curves from each of the 100 bootstrap
replicates. The 100 results were integrated into a final result
using Rubin’s rule. Therefore, the final results not only incorpo-
rate the standard errors of the GEE models but also take into
account the uncertainty of the reference percentile curves.
EDSS worsening was defined as an increase in EDSS since pre-
vious SMSC visit of 1.5 points from an EDSS score of 0.0,
1.0 point from an EDSS score of 1.0 to 5.5, or 0.5 point
from an EDSS score 6.0 (median duration between visits 5
6.4 months, IQR 5 5.2–11.7). GEEs using a Poisson distribu-
tion were used to compare the incidence of relapses between
percentile categories and calculate incidence rate ratios (IRRs)
with 95% CIs. The models were tested for overdispersion,35
and the null hypothesis of equidispersion was not violated in
any model. As a sensitivity analysis, negative binomial mixed
effect models were used. However, these models tended to not
converge further, supporting the use of a Poisson distribution.
GEE models were similarly used to model binary outcomes (eg,
presence vs absence of relapses and presence vs absence of
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EDSS increase) and estimate odds ratios (ORs) with 95% CIs.
For all models, model-predicted means (marginal means) and
95% CIs were calculated using the lsmeans package36 and pre-
dicted odds were converted to probabilities (p 5 odds / [1 1
odds]). All analyses in which NfL was used to predict past and
future clinical events were performed on a subset of the data
excluding samples within 30 days after a relapse. As a sensitivity
analysis, all analyses were repeated using all samples (ie, without
removing samples shortly after a relapse) and using only the
last sample at which patients were under similar conditions
using generalized linear models (data not shown). The quality
of all models was investigated by visually inspecting residuals
and quantile–quantile plots. All analyses were conducted using
the statistical software R.37
Results
sNfL Levels in HC
AGE, GENDER, AND TEMPORAL VARIATION. Most
HC were females (n 5 173, 68.1%), and the median
age was 44.3 (IQR 5 36.4–52.4) years. The median
sNfL concentration was 22.9 (IQR 5 16.8–31.4) pg/ml,
with no statistically significant difference between males
and females (23.4 [IQR 5 17.1–32.1] vs 22.8 [IQR 5
16.6–30.3] pg/ml; b 5 1.032, 95% CI 5 0.910–1.171,
p 5 0.622). A positive association was instead observed
between sNfL and age, with a 2.2% increase in sNfL for
each additional year (b 5 1.022, 95% CI 5 1.018–
1.026, p < 0.001). Accordingly, median sNfL slightly
increased (by 1.8%) in the 87 HC with a second serum
sample after a median FU time of 367 (IQR 5 364–
385) days (baseline: 27.3 [IQR 5 20.3–35.2] pg/ml;
FU: 27.8 [IQR 5 22.1–36.3] pg/ml). There was no
association between sNfL and storage time (b 5 0.959,
95% CI 5 0.906–1.016, p 5 0.157 after age
correction).
REFERENCE PERCENTILE CURVES. The distribution
of sNfL across different ages was modeled by using
GAMLSS (see Subjects and Methods). The resulting
80th, 90th, 95th, 97.5th, and 99th sNfL percentiles are
presented in Table 1.
sNfL Levels in the Lugano Cohort
DEMOGRAPHIC AND CLINICAL VARIABLES. Serum
and paired CSF samples were available in 142 and 132
patients. The median age was 37.9 (IQR 5 29.8–47.8)
years, and 92 (64.8%) were female. There were 48
(33.8%) CIS, 62 (43.7%) RRMS, 16 (11.3%) PPMS, 3
(2.1%) SPMS, and 13 (9.1%) RIS patients. Brain and
spinal cord MRI data were available at time of sample
collection for 142 and 124 individuals, respectively. The
median time between sample collection and the acquisi-
tion of brain and spinal cord MRI images was 5.0
(IQR 5 1.0–19.5) and 13.0 (IQR 5 4.0–30.0) days,
respectively.
SERUM AND CSF NFL. Median NfL in serum (35.9
[IQR 5 22.1–61.7] pg/ml) was 42-fold lower than that
in CSF (1,521.1 [IQR 5 814.1–2,888.1] pg/ml). There
was a strong positive association between CSF NfL and
sNfL levels, with a 10% increase in CSF leading to a
5.9% higher sNfL (log10[sNfL] 5 0.0509 1 0.589 3
TABLE 1. Estimated sNfL Percentiles Including Bootstrap Confidence Intervals across Different Ages Calcu-
lated Based on sNfL from Healthy Control Samples
sNfL Percentiles, pg/ml
Age, yr 80th 90th 95th 97.5th 99th
30 20.9 (19.3–22.4) 24.3 (22.3–26.3) 27.9 (25.1–30.4) 31.6 (27.6–35.7) 37.2 (30.9–44.4)
35 23.3 (21.9–24.9) 27.1 (25.3–29.2) 31.1 (28.6–34.0) 35.2 (31.7–39.6) 41.5 (35.8–49.4)
40 26.0 (24.7–27.5) 30.3 (28.6–32.3) 34.7 (31.9–37.8) 39.3 (35.4–44.0) 46.3 (40.1–54.9)
45 29.1 (27.7–30.7) 33.9 (32.2–35.9) 38.9 (36.1–41.9) 44.1 (39.8–49.2) 51.9 (44.8–61.5)
50 32.7 (31.1–34.8) 38.1 (35.9–40.3) 43.6 (40.7–47.0) 49.5 (44.7–55.4) 58.3 (50.3–69.4)
55 36.5 (34.2–39.2) 42.5 (39.7–45.4) 48.7 (45.4–52.5) 55.2 (50.4–61.6) 65.0 (56.2–77.3)
60 40.5 (37.7–44.0) 47.2 (43.6–51.0) 54.0 (49.6–58.8) 61.3 (55.4–68.1) 72.1 (62.3–85.1)
65 44.6 (41.0–49.1) 52.0 (47.3–57.1) 59.5 (53.4–65.8) 67.5 (60.0–75.9) 79.5 (68.2–93.4)
70 48.8 (44.2–54.3) 56.9 (51.1–63.4) 65.1 (57.2–73.2) 73.9 (64.3–84.0) 87.0 (73.8–102.7)
sNfL 5 serum neurofilament light chain.
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log10[NfLCSF] p< 0.001; Pearson r 5 0.77, 95% CI 5
0.69–0.83, p < 0.001; Fig 1A).
sNfL IN PATIENTS AND CONTROLS AND ASSOCIA-
TIONS WITH MRI. As in HC samples, sNfL was posi-
tively associated with age (b 5 1.015, 95% CI 5
1.006–1.025, p 5 0.002), but not with gender (b 5
1.165, 95% CI 5 0.911–1.489, p 5 0.226). There was
no association between sNfL and storage time (b 5
1.030, 95% CI 5 0.977–1.086, p 5 0.274, after age
correction). All remaining analyses were corrected by
including age as a covariate in the regression models.
Patients had higher sNfL levels than HC (b 5 1.914,
95% CI 5 1.717–2.135, p < 0.001). In addition, sNfL
progressively increased with increasing number of T2
and gadolinium-enhancing (GE) lesions in both brain
and spinal cord (Table 2 and Fig 1B, C). Median sNfL
levels progressively increased from 29.6 (IQR 5 20.9–
41.8) pg/ml in patients with GE lesions in neither brain
nor spinal cord, to 43.4 (IQR 5 25.2–65.3) pg/ml in
those with GE lesions in either brain or spinal cord, to
62.5 (IQR 5 42.7–71.4) pg/ml in those with GE
lesions in both brain and spinal cord (either vs neither:
b 5 1.461, 95% CI 5 1.128–1.892, p 5 0.005; both
vs neither: b 5 1.902, 95% CI 5 1.278–2.830, p 5
0.002; both vs either: b 5 1.302, 95% CI 5 0.861–
1.969, p 5 0.213; see Table 2 and Fig 1D).
sNfL Levels in the SMSC
DEMOGRAPHIC, CLINICAL VARIABLES, AND TREAT-
MENT SWITCHES. Three and 2 serum samples were
available for 227 and 19 patients, respectively (ie, total
number of samples 5 719). Most patients started or
switched to a new DMT shortly after baseline sample
(“starters”; n 5 212, 86.2%), whereas 34 (13.8%) were
patients with progressive MS who were either untreated or
on continuous DMT (“nonstarters”). The median time
between baseline sampling and DMT initiation in the
starters group was 41 (IQR 5 5.0–93.8) days. Demo-
graphic and clinical characteristics are shown in Table 3.
ASSOCIATIONS BETWEEN sNfL AND DEMOGRAPHIC
AND CLINICAL VARIABLES. The median sNfL level in
the SMSC cohort was 29.4 (IQR 5 20.1–45.2) pg/ml.
FIGURE 1: (A) Association between cerebrospinal fluid (CSF) neurofilament light chain (NfL) and serum neurofilament light
chain (sNfL) levels in the Lugano cohort. A 10% increase in CSF NfL corresponds to an increase of approximately 5.9% in sNfL
(b 5 0.589, p < 0.001). Gray band: 95% confidence interval. (B) Association between brain T2 lesion load and sNfL levels in the
Lugano cohort (2–9 vs 0–1: b 5 1.849, p 5 0.001; >9 vs 0–1: b 5 2.524, p < 0.001). (C) Association between number of brain
gadolinium-enhancing (GE) lesions and sNfL levels in the Lugano cohort (1 vs 0: b 5 1.077, p 5 0.630; 2 vs 0: b 5 1.551, p 5
0.024; 3 vs 0: b 5 2.138, p 5 0.001). (D) Association between brain and spinal cord GE lesions and sNfL levels in the Lugano
cohort (either brain or spinal vs neither: b 5 1.461, p 5 0.005; both brain and spinal vs neither: b 5 1.902, p 5 0.002).
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Several variables were tested for association with sNfL in
all patients (n 5 246; Table 4). As in the HC and
Lugano cohorts, sNfL levels were positively associated
with age (b 5 1.018, 95% CI 5 1.012–1.024, p <
0.001) and no gender association was detected (see Table
4). Storage time was not significantly associated with
sNfL (b 5 1.048, 95% CI 5 0.999–1.099, p 5 0.057
after age correction). Disease duration was also signifi-
cantly associated with sNfL (b 5 1.011, 95% CI 5
1.003–1.018, p 5 0.004). However, this association dis-
appeared when correcting for age (b 5 1.001, 95% CI
5 0.993–1.010, p 5 0.755), whereas the age association
TABLE 2. sNfL Concentration and Associations with Different Clinical and Magnetic Resonance Imaging Varia-
bles in the Lugano Cohort
Variable Median (IQR)/
No. (%)
sNfL, Median (IQR),
pg/ml
b 95% CI p
Age, yr 37.9 (29.8–47.8) — 1.015 1.006–1.025 0.002
Gender
F 92 (64.8%) 33.0 (21.5–55.3) — — —
M 50 (35.2%) 44.2 (25.7–62.4) 1.165 0.911–1.489 0.226
Oligoclonal bands
Negative 13 (9.1%) 26.8 (16.8–49.6) — — —
Positive 129 (90.9%) 36.2 (22.7–61.9) 1.114 0.740–1.676 0.606
Brain T2 lesions
0–1 16 (11.3%) 17.3 (11.1–21.8) — — —
2–9 61 (43.0%) 30.2 (21.4–49.6) 1.849 1.283–2.666 0.001
>9 65 (45.7%) 48.0 (30.9–69.7) 2.524 1.744–3.653 <0.001
Brain GE lesions
0 89 (63.6%) 32.7 (21.3–49.7) — — —
1 26 (18.6%) 31.6 (22.6–55.3) 1.077 0.797–1.456 0.630
2 15 (10.7%) 58.3 (28.4–77.0) 1.551 1.064–2.259 0.024
3 10 (7.1%) 61.6 (46.4–89.1) 2.138 1.362–3.355 0.001
Spinal T2 lesions
0 31 (25.0%) 26.4 (17.2–42.8) — — —
1 26 (21.0%) 25.4 (18.5–42.5) 0.819 0.574–1.167 0.271
2 67 (54.0%) 44.0 (29.6–64.6) 1.332 0.992–1.788 0.059
Spinal GE lesions
0 95 (78.5%) 32.4 (21.5–53.5) — — —
1 26 (21.5%) 49.2 (30.9–66.0) 1.467 1.091–1.974 0.013
Brain/spinal GE lesions
Neither 63 (52.9%) 29.6 (20.9–41.8) — — —
Either 43 (36.1%) 43.4 (25.2–65.3) 1.461 1.128–1.892 0.005
Both 13 (10.9%) 62.5 (42.7–71.4) 1.902 1.278–2.830 0.002
Age was included as additional variable in all models.
CI 5 confidence interval; F 5 female; GE 5 gadolinium-enhancing; IQR 5 interquartile range; M 5 male; sNfL 5 serum neurofilament light
chain.
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was unchanged (b 5 1.016, 95% CI 5 1.008–1.023,
p< 0.001). This implies disease duration as a proxy for
age, and only the latter was therefore considered in
following analyses. The age association was present
and of similar strength in both CIS/RRMS and PPMS/
SPMS patients (b 5 1.015, 95% CI 5 1.007–1.023,
TABLE 3. Descriptive Statistics of Demographic and Clinical Variables of the SMSC Patients at Baseline
Variables SMSC,
n 5 246
SMSC Starters,
n 5 212
SMSC Nonstarters,
n 5 34
Age, yr 42.2 (33.6–51.4) 40.6 (32.8–48.8) 54.5 (49.2–60.9)
Gender
F 162 (65.9%) 151 (71.2%) 11 (32.4%)
M 84 (34.1%) 61 (28.8%) 23 (67.6%)
Diagnosis at baseline
CIS 14 (5.7%) 14 (6.6%) 0 (0.0%)
RRMS 185 (75.2%) 185 (87.3%) 0 (0.0%)
SPMS 27 (11.0%) 11 (5.2%) 16 (47.1%)
PPMS 20 (8.1%) 2 (0.9%) 18 (52.9%)
Disease duration, yr 7.4 (1.8–15.3) 6.6 (1.6–14.3) 15.3 (7.9–23.7)
EDSS 3.0 (1.5–4.0) 2.5 (1.5–3.5) 4.8 (3.6–6.0)
DMT at baseline
Injectable DMTs 77 (31.3%) 73 (34.4%) 4 (11.8%)
Natalizumab 22 (8.9%) 22 (10.4%) 0 (0.0%)
Fingolimod 9 (3.7%) 9 (4.2%) 0 (0.0%)
Azathioprine 4 (1.6%) 4 (1.9%) 0 (0.0%)
Mitoxantrone 6 (2.4%) 3 (1.4%) 3 (8.8%)
Dimethyl fumarate 2 (0.8%) 2 (0.9%) 0 (0.0%)
Rituximab 1 (0.4%) 1 (0.5%) 0 (0.0%)
Other 4 (1.6%) 0 (0.0%) 4 (11.8%)
Untreated 121 (49.2%) 98 (46.2%) 23 (67.6%)
Switch after baseline to
Fingolimod — 136 (64.2%) —
Injectable DMTs — 39 (18.4%) —
Natalizumab — 21 (9.9%) —
Rituximab — 16 (7.5%) —
Baseline to first follow-up, days 224.0 (188.0–368.0) 217.0 (183.5–365.0) 363.5 (335.2–377.2)
Baseline to second follow-up, days 540.0 (386.0–725.5) 511.0 (383.5–700.8) 731.0 (664.5–753.0)
Baseline to new DMT start, days — 41.0 (5.0–93.8) —
Values are median (interquartile range) or count (percentage). SMSC Starters 5 patients starting or switching to a new DMT after baseline sam-
pling. SMSC Nonstarters 5 progressive multiple sclerosis patients who were either untreated or had not changed DMT.
CIS 5 clinically isolated syndrome; DMT 5 disease-modifying treatment; EDSS 5 Expanded Disability Status Scale; F 5 female; M 5 male;
PPMS 5 primary progressive multiple sclerosis; RRMS 5 relapsing–remitting multiple sclerosis; SMSC 5 Swiss Multiple Sclerosis Cohort Study;
SPMS 5 secondary progressive multiple sclerosis.
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p < 0.001 and b 5 1.015, 95% CI 5 1.003–1.028,
p5 0.016; Fig 2A). Both groups had higher sNfL than
HC, even after correcting for age (CIS/RRMS: 27.2
[IQR 5 19.2–57.2] pg/ml, b 5 1.418, 95% CI 5
1.288–1.560, p < 0.001; PPMS/SPMS: 41.4 [IQR 5
32.1–57.2] pg/ml, b 5 1.620, 95% CI 5 1.417–1.851,
p < 0.001; see Fig 2B). sNfL concentrations were
higher in PPMS/SPMS as compared to CIS/RRMS (b
5 1.450, 95% CI 5 1.245–1.688, p < 0.001; after
correcting for age: b 5 1.205, 95% CI 5 1.106–1.418,
p 5 0.029). Positive associations were also found in
univariate analyses between sNfL and EDSS (b 5
1.141, 95% CI 5 1.106–1.178, p < 0.001; see
Fig 2C), presence of a relapse within 60 days before
sampling (b 5 1.563, 95% CI 5 1.303–1.874,
p < 0.001), and recent EDSS worsening (b 5 1.294,
95% CI 5 1.090–1.536, p 5 0.003). Noteworthy,
sNfL levels were lower in DMT-treated versus untreated
patients (b 5 0.717, 95% CI 5 0.634–0.810,
p < 0.001).
All following variables were then included in the
same multivariate model: age, gender (female vs male),
EDSS, disease course (CIS/RRMS vs PPMS/SPMS),
presence of relapses within 60 days before sampling (yes
vs no), recent EDSS worsening (yes vs no), and DMT
treatment status (treated vs untreated). sNfL levels
remained significantly associated with age, EDSS, pres-
ence of relapses within 60 days before sampling, and
DMT treatment status (see Table 4). Disease course
(CIS/RRMS vs PPMS/SPMS) did not survive as an
TABLE 4. Univariate and Multivariate Models Testing Associations between Age, Gender, EDSS, Disease
Course, Recent Relapses, Recent EDSS Worsening, and DMT Status and sNfL in the SMSC Cohort
Univariate Multivariate
Variable
(sample No.)
sNfL, pg/ml
[IQR] b 95% CI p b 95% CI p
Age (719) — 1.018 1.012–1.024 <0.001 1.012 1.005–1.019 <0.001
Gender
F (474) 29.1 [20.1–44.3] — — — — — —
M (245) 30.9 [20.2–48.0] 1.054 0.902–1.232 0.505 0.991 0.858–1.145 0.905
EDSS (719) — 1.141 1.106–1.178 <0.001 1.105 1.063–1.149 <0.001
Disease course
CIS/RRMS (581) 27.2 [19.2–57.2] — — — — — —
PPMS/SPMS (138) 41.4 [32.1–57.2] 1.450 1.245–1.688 <0.001 0.924 0.742–1.151 0.483
Recent relapse, <60 days
No (643) 28.9 [20.0–43.8] — — — — — —
Yes (76) 39.3 [25.9–60.2] 1.563 1.303–1.874 <0.001 1.430 1.156–1.768 <0.001
Recent EDSS worsening
No (615) 29.0 [20.1–43.9] — — — — — —
Yes (51) 38.5 [27.8–64.0] 1.294 1.090–1.536 0.003 1.119 0.962–1.303 0.146
DMT
Untreated (162) 38.0 [23.8–56.7] — — — — — —
DMT treated (557) 27.0 [20.1–45.2] 0.717 0.634–0.810 <0.001 0.818 0.716–0.934 0.003
The number of samples for each variable is indicated within parentheses (eg, number of samples collected in patients under treatment at time of
sampling 5 557, number of samples collected in patients untreated at time of sampling 5 162). Information on age, gender, EDSS, disease course,
recent relapses, and DMT treatment was available for 719 (100%) sampling time points. No data were available for preceding EDSS scores at 53
(7.4%) sampling time points.
CI 5 confidence interval; CIS 5 clinically isolated syndrome; DMT 5 disease-modifying treatment; EDSS 5 Expanded Disability Status Scale;
F 5 female; M 5 male; PPMS 5 primary progressive multiple sclerosis; RRMS 5 relapsing–remitting multiple sclerosis; SMSC 5 Swiss Multiple
Sclerosis Cohort Study; sNfL 5 serum neurofilament light chain; SPMS 5 secondary progressive multiple sclerosis.
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independent factor. We tested potential interactions
between variables of interest, and observed that the
increase in sNfL per EDSS unit increase was lower in
PPMS/SPMS than in CIS/RRMS patients (b 5 1.024,
95% CI 5 0.952–1.101 vs b 5 1.133, 95% CI 5
1.081–1.187, respectively; interaction p 5 0.021; see Fig
2D, Supplementary Table 1).
ASSOCIATIONS BETWEEN sNfL AND TIME UNDER
NEW TREATMENT. Baseline sNfL levels were higher
in patients starting natalizumab (50.8 [IQR 5 20.8–
77.0] pg/ml) and rituximab (51.0 [IQR 5 29.1–71.4]
pg/ml) than those initiating fingolimod (29.8 [IQR 5
20.7–46.4] pg/ml) and injectable DMTs (28.1 [IQR 5
18.0–43.2] pg/ml). sNfL levels at baseline were higher
in all patient groups as compared to HC (p < 0.001 for
all; Fig 3). We explored the association between time
under treatment and sNfL during FU while correcting
for baseline sNfL and other covariates. After adjustment,
time since start of new treatment in years was negatively
associated with FU sNfL (b 5 0.900, 95% CI 5
0.830–0.976, p 5 0.011; see Fig 3, Supplementary
Table 2). The decrease in sNfL with time since start of
new treatment appeared similar across different DMTs,
but numbers were too low to investigate differences
further.
sNfL and Previous and Future Disease Activity
Finally, we investigated whether high sNfL levels were
associated with past and future clinical disease activity
(relapses and EDSS worsening). To this purpose, we
compared sNfL measurements from the SMSC against
the age-corrected percentile curves that were constructed
based on HC samples. To have a more homogeneous
population, this analysis was only performed in CIS/
RRMS patients. Of a total of 581 samples, 287 (49.4%)
samples had sNfL values above the 80th percentile, 228
(39.2%) above the 90th percentile, 171 (29.4%) above
the 95th percentile, 135 (23.2%) above the 97.5th per-
centile, and 105 (18.1%) above the 99th percentile. The
median FU time after sample collection was 3.1 (IQR 5
2.0–4.0) years.
FIGURE 2: (A) Association between age and serum neurofilament light chain (sNfL) levels in healthy controls (HC), clinically iso-
lated syndrome (CIS)/relapsing–remitting multiple sclerosis (RRMS) patients, and primary progressive multiple sclerosis (PPMS)/
secondary progressive multiple sclerosis (SPMS) patients from the Swiss Multiple Sclerosis Cohort Study (SMSC) cohort. An
increase of 1 year in age corresponds to an increase of approximately 2.2%, 1.5%, and 1.5% in sNfL in the 3 groups, respec-
tively. Gray band: 95% confidence interval (CI). (B) sNfL in HC versus CIS/RRMS and SPMS/PPMS from the SMSC cohort. (C)
Association between Expanded Disability Status Scale (EDSS) and sNfL levels in the SMSC cohort. A 1-point EDSS increase cor-
responds to an sNfL increase of approximately 14.1%. Gray band: 95% CI. (D) Significant interaction between EDSS and dis-
ease course (CIS/RRMS vs PPMS/SPMS) in the association with sNfL in the SMSC cohort (interaction b 5 0.904, interaction p 5
0.021). Gray shading: 95% CI.
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PREVIOUS CLINICAL DISEASE ACTIVITY (RELAPSES,
ARR, AND EDSS WORSENING). The probability of
having experienced a relapse within 60 days before sam-
pling was increased for sNfL measurements above versus
below the 80th, 90th, 95th, 97.5th, and 99th percentiles
(Fig 4A, Supplementary Table 3). Patients with sNfL
above the 97.5th percentile had approximately 4.0-fold
odds of having experienced a relapse in the previous
60 days (OR 5 3.89, 95% CI 5 2.30–6.58, p <
0.001). The mean ARR during 1 and 2 years before
sample collection was higher in patients with sNfL lev-
els above these percentiles (see Fig 4A, Supplementary
Table 3). The incidence of relapses 1 and 2 years
before sample collection was approximately 1.5 to 2.0
times higher with sNfL levels above the 97.5th percen-
tile (IRR 5 2.08, 95% CI 5 1.64–2.63, p < 0.001
and IRR 5 1.39, 95% CI 5 1.18–1.64, p < 0.001,
respectively).
The probability of having experienced worsening of
the EDSS within 6 to 12 months before sampling was
higher in patients with sNfL values above versus below
the 90th, 95th, 97.5th, and 99th percentiles (see Fig 4A,
Supplementary Table 3). Patients with sNfL above the
97.5th percentile had >4.0-fold odds of having experi-
enced EDSS worsening in the previous 6 to 12 months
(OR 5 4.36, 95% CI 5 2.09–9.09, p < 0.001). Nota-
bly, there was a strikingly progressive probability of hav-
ing experienced past relapses or EDSS worsening with
increasing percentile categories.
FUTURE CLINICAL DISEASE ACTIVITY (ARR AND
EDSS WORSENING). The mean ARR was increased
during 1 and 2 years after the collection of samples with
sNfL levels above the 80th, 90th, 95th, 97.5th, and 99th
percentiles (see Fig 4B, Supplementary Table 4). The
incidence of relapses was approximately 2.0 times higher
both 1 and 2 years after the collection of samples with
sNfL levels above the 97.5th percentile (IRR 5 1.94,
95% CI 5 1.21–3.10, p 5 0.006 and IRR 5 1.96,
95% CI 5 1.22–3.15, p 5 0.005). The proportion of
patients experiencing EDSS worsening within 12 months
after sampling gradually increased with increasing sNfL
percentile category (from 6.7% for samples <80th per-
centile to approximately 15% for samples >97.5th per-
centile; OR 5 2.41, 95% CI 5 1.07–5.42, p 5 0.034;
see Fig 4B, Supplementary Table 4).
FIGURE 3: Baseline serum neurofilament light chain (sNfL) was higher in patients starting natalizumab (50.8pg/ml) and rituxi-
mab (51.0pg/ml) than in those initiating fingolimod (29.8pg/ml) and injectable disease-modifying treatments (DMTs; 28.1pg/
ml). sNfL levels decreased in patients starting injectable DMTs, fingolimod, natalizumab, or rituximab over time. HC 5 healthy
controls.
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Discussion
Several candidate biomarkers have been proposed in
MS,2 but their clinical relevance remains uncertain and
none is currently accepted as a sensitive and reliable mea-
sure to monitor disease course in clinical practice. In 2
independent cohorts of patients, we provide evidence
that measurement of sNfL has several features necessary
to qualify as an urgently needed laboratory marker of
neuronal damage in MS. sNfL levels are not only signifi-
cantly higher in MS patients versus controls, they corre-
late with focal lesion presence and activity in both the
brain and the spinal cord, as depicted by MRI but also
with relevant static and dynamic clinical outcomes, that
is, previous, concurrent, and future relapses and disability
worsening.
Our results confirm and expand on previous stud-
ies20,21 showing that NfL can be reliably measured in
serum using the Simoa technology, even at very low con-
centrations (down to a few pg/ml). The observed increase
of NfL levels in serum with age seen in both HC and
patient cohorts mirrors the age association described for
CSF NfL levels,38 and it is best explained by ongoing
age-related neuronal degeneration. We did not observe a
difference in sNfL between genders. The tight positive
association between CSF and sNfL levels highlights that
serum levels closely reflect NfL release within the central
nervous system, as already indicated by previous
studies.19,39,40
Both patient cohorts included in this study had
higher sNfL concentration than healthy individuals. This
confirms what has been observed in CSF NfL stud-
ies4,7,10–12,41–44 and the results of a single previous inves-
tigation of CIS patients in which sNfL levels were
measured using a less sensitive ECL assay.18 sNfL levels
were also slightly higher in the Lugano than in the
SMSC samples, likely because the former were collected
as part of the diagnostic workup, which is frequently per-
formed shortly after relapses. The close association of
increased blood NfL levels with neuronal damage has
been suggested in other neurological conditions, includ-
ing ALS, neurodegenerative disorders, and acute brain
and spinal cord injury.8,22–24,39,40 In conjunction with
findings in other neurological diseases, our results in MS
strongly suggest that increased sNfL levels reflect ongoing
neuronal damage irrespective of the underlying patho-
genic mechanism.
The relation between neuronal damage and NfL
concentration is also supported by the clear positive asso-
ciation between sNfL and focal inflammatory MRI
lesions in both brain and spinal cord. We found gradu-
ally increased sNfL levels in patients with higher brain
T2 and GE lesion counts. A similar significant
FIGURE 4: Model-predicted means (marginal means) and model estimates including 95% confidence intervals from generalized esti-
mating equation models. (A) Probability of a recent relapse (within 60 days before sampling), annualized relapse rate (ARR) in the 1
year before sampling, and probability of Expanded Disability Status Scale (EDSS) worsening since 6 to 12 months before sampling
according to serum neurofilament light chain (sNfL) percentiles. (B) ARR in the 1 year after sampling, ARR in the 2 years after sampling,
and probability of EDSS worsening within 1 year after sampling according to sNfL percentiles. There were 287 samples (49.4%) with
sNfL values above the 80th percentile, 228 samples (39.2%) above the 90% percentile, 171 samples (29.4%) above the 95th percen-
tile, 135 samples (23.2%) above the 97.5th percentile, and 105 (18.1%) above the 99th percentile.
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association was found between sNfL and presence of spi-
nal GE lesions and was most pronounced when GE
lesions were present in both brain and spinal cord. Sev-
eral studies have shown associations between CSF NfL
and brain T2 and GE lesions.7,12,45 We have also previ-
ously shown weak associations between sNfL (as mea-
sured by the ECL assay) and brain T2 and GE lesions in
CIS patients18 and in a small cohort of RRMS patients
(n 5 29).19 Our current results confirm and expand
these findings in a larger cohort of patients and suggest
that spinal cord damage also contributes to increased
NfL concentrations in serum. This appears to be rele-
vant, because spinal cord pathology is a key factor in the
development of disability in MS.27,46
We made use of the longitudinal SMSC cohort
with repeated measurements to simultaneously analyze
the association between several clinical variables and
sNfL. In addition to age, both presence of a recent
relapse and disability as measured by the EDSS were pos-
itively and independently associated with sNfL. This sug-
gests sNfL levels may be related to both acute
inflammatory damage and chronic diffuse neuronal loss
leading to disability progression in its proper sense. Inter-
estingly, the EDSS association was more evident in CIS/
RRMS than in PPMS/SPMS patients, perhaps resem-
bling the slower and gradual disability accumulation
characterizing progressive MS. It may also be an indica-
tion that disease progression in this later stage of disease
reflects both direct tissue damage and reduced/exhausted
compensation capacity.
Of particular interest in the search for biomarkers
reflecting therapeutic effects is that sNfL levels were sig-
nificantly lower in DMT-treated as compared to
untreated patients, independently of all other variables.
In CIS/RRMS patients, the decrease in sNfL levels corre-
lated inversely with longer time since start of DMTs
independent of recent relapses. Notably, treatment effects
on CSF NfL levels have already been shown for fingoli-
mod, natalizumab, and rituximab in MS patients.13–17,47
Although this study was not primarily designed to inves-
tigate treatment effects, our results suggest that DMTs
reduce sNfL levels, supporting their value for monitoring
treatment response.
Patients with sNfL levels above different HC-based
percentiles had considerably higher risk of having experi-
enced a recent relapse or EDSS worsening. sNfL measure-
ments could therefore be used to indicate recent neuronal
damage, and this could be particularly useful in case of
“clinically silent disease” or when clinical changes are diffi-
cult to interpret. Moreover, high sNfL levels were also associ-
ated with a higher risk of future clinical relapses and EDSS
worsening. This confirms findings from 2 relatively small
studies suggesting that patients with higher CSF neurofila-
ment levels have a worse long-term disease outcome.48,49
Taken together, these results support the potential use of
sNfL as a prognostic marker of clinical disease course.
Our study has some limitations. Only a single stan-
dardized high-resolution MRI scan was available as part of
the clinical diagnostic workup of the Lugano cohort, and
no lesion volume measurements were available in addition
to the T2 lesion counts to test for association with sNfL.
Second, the FU in the SMSC cohort was relatively short
and did not allow an estimate of sNfL association with
long-term disease worsening or progression. The observa-
tional study design does not allow separation of potential
treatment effects from regression to the mean phenomena
in this relatively active cohort of patients. The percentile
curves are currently based on a limited number of HC
samples (n 5 254), and we did not include information
on comorbidities and vascular risk factors. This will need
to be assessed in the future, as we move to application of
this measure in individual patients. Finally, samples were
stored in different facilities and for different storage peri-
ods, but collection procedures were standardized,25 and
we did not observe an association between storage time
and sNfL in either patient or control cohorts.
Based on the investigation of HC and 2 large inde-
pendent samples of MS patients with the recently devel-
oped ultrasensitive sNfL assay, this study provides a
number of important findings that further our under-
standing and support the value of sNfL levels as a bio-
marker of tissue damage in MS: (1) sNfL levels can be
reliably and reproducibly measured in serum samples
from MS patients; (2) in independent HC and patient
cohorts, sNfL levels are positively associated with age but
not gender; (3) sNfL levels closely reflect NfL concentra-
tion in the CSF of MS patients; (4) sNfL levels are
increased in MS patients as compared to HC and posi-
tively associated with T2 and GE lesions in both brain
and spinal cord; (5) sNfL levels are increased in patients
with recent relapses or worsening of disability, are higher
with increasing EDSS scores, and decrease with increas-
ing duration of DMT; and (6) sNfL levels are associated
with an increased risk of future relapses and EDSS wors-
ening. These findings indicate that sNfL may have a role
in assessing disease severity and worsening, as well as in
monitoring the effect of DMT. Before sNfL is imple-
mented in clinical practice, more data and research will
be needed to establish reference ranges in the general
population and sensitivity and specificity of NfL-based
predictions, by using larger cohorts of controls, and tak-
ing into account relevant comorbidities and treatment
effects. Assay protocols will need to be standardized and
validity of the assay will need to be tested across different
ANNALS of Neurology
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centers.50 Ongoing investigations of samples obtained in
the setting of prospective controlled clinical trials will
help to further elucidate the utility of sNfL measure-
ments in monitoring treatment effects.51
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